Apixaban (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Apixaban" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

8fda.gov

447^th place

338^th place

5doi.org

2^nd place

4web.archive.org

1^st place

2drugs.com

399^th place

333^rd place

2europa.eu

68^th place

117^th place

2pfizer.com

low place

2clincalc.com

3,912^th place

2,496^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1biospace.com

low place

7,595^th place

1nice.org.uk

3,258^th place

2,666^th place

1semanticscholar.org

11^th place

8^th place

1medpagetoday.com

9,274^th place

5,856^th place

1medicaldialogues.in

low place

1jdsupra.com

low place

1biopharmadive.com

low place

1natlawreview.com

9,177^th place

5,024^th place

1drugstorenews.com

low place

1apotex.com

low place

1fiercepharma.com

low place

8,921^st place

1nbcnews.com

137^th place

101^st place

1hhs.gov

5,973^rd place

3,693^rd place

apotex.com

"First Generic Alternative to Eliquis Now Available in Canada". Apotex (Press release). 20 July 2022. Retrieved 29 June 2023.

biopharmadive.com

"Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug". BioPharma Dive. Retrieved 30 November 2021.

biospace.com

"With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now". BioSpace. 6 August 2020. Retrieved 29 November 2021.

books.google.com

Kiser K (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Apixaban Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E (2013). "Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups". Thrombosis. 2013: 640723. doi:10.1155/2013/640723. PMC 3885278. PMID 24455237.
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. (December 2018). "Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review". Annals of Internal Medicine. 169 (11): 774–787. doi:10.7326/M18-1523. PMC 6825839. PMID 30383133.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. (February 2013). "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects". British Journal of Clinical Pharmacology. 75 (2): 476–487. doi:10.1111/j.1365-2125.2012.04369.x. PMC 3558798. PMID 22759198.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978. S2CID 43262809.
Cada DJ, Levien TL, Baker DE (June 2013). "Apixaban". Hospital Pharmacy. 48 (6): 494–509. doi:10.1310/hpj4806-494. PMC 3839491. PMID 24421512.

drugs.com

"Apixaban (Eliquis) Use During Pregnancy". Drugs.com. 21 June 2019. Retrieved 13 August 2020.
"Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.

drugstorenews.com

Levy S (1 August 2022). "Apotex offers generic Eliquis in Canada". Drugstore News. Retrieved 2 September 2022.

europa.eu

ema.europa.eu

"Eliquis EPAR". European Medicines Agency. 17 September 2018. Retrieved 22 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"No change is needed in use of direct oral anticoagulants following EMA-funded study". European Medicines Agency (EMA). 27 March 2020. Retrieved 22 April 2020.

fda.gov

"FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. This article incorporates text from this source, which is in the public domain.
"Atrial fibrillation and new oral anticoagulant drugs". U.S. Food and Drug Administration (FDA). 2 December 2015. Retrieved 22 April 2020.
"Atrial fibrillation, oral anticoagulant drugs, and their reversal agents". U.S. Food and Drug Administration. 2 December 2015. Retrieved 22 April 2020.
"Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)". U.S. Food and Drug Administration (FDA). 31 December 2018. Retrieved 22 April 2020.
"2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). 5 August 2020. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

accessdata.fda.gov

"Drug Approval Package: Eliquis (apixaban) NDA #202155". U.S. Food and Drug Administration (FDA). 13 February 2013. Retrieved 23 December 2019.
"FDA-Approved Drugs: Eliquis (apixaban)". U.S. Food and Drug Administration (FDA). Retrieved 23 December 2019.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

fiercepharma.com

Kansteiner F (29 August 2023). "Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS". Retrieved 31 August 2023.

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

hhs.gov

aspe.hhs.gov

"Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices" (PDF). Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. 15 August 2024.

jdsupra.com

"Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc". JD Supra. Retrieved 30 November 2021.

medicaldialogues.in

business.medicaldialogues.in

"FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis". Business Medical Dialogues. New Delhi, India: Minerva Medical Treatment. 24 December 2019. Retrieved 24 December 2019.

medicines.org.uk

"Eliquis 5 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 3 May 2022. Retrieved 8 October 2022.

medpagetoday.com

Neale T (14 March 2014). "FDA OKs Apixaban for DVT Prevention". MedPage Today. Retrieved 17 September 2015.

natlawreview.com

"Federal Circuit Crystallizes BMS' Apixaban District Court Win". The National Law Review. Retrieved 30 November 2021.

nbcnews.com

Lovelace Jr B (15 August 2024). "Medicare announces lower prices on 10 common, high-cost drugs". NBC News. Retrieved 21 August 2024.

nice.org.uk

"Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation" (PDF). National Institute for Health and Care Excellence. January 2013. Retrieved 26 February 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E (2013). "Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups". Thrombosis. 2013: 640723. doi:10.1155/2013/640723. PMC 3885278. PMID 24455237.
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. (December 2018). "Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review". Annals of Internal Medicine. 169 (11): 774–787. doi:10.7326/M18-1523. PMC 6825839. PMID 30383133.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. (February 2013). "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects". British Journal of Clinical Pharmacology. 75 (2): 476–487. doi:10.1111/j.1365-2125.2012.04369.x. PMC 3558798. PMID 22759198.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978. S2CID 43262809.
Cada DJ, Levien TL, Baker DE (June 2013). "Apixaban". Hospital Pharmacy. 48 (6): 494–509. doi:10.1310/hpj4806-494. PMC 3839491. PMID 24421512.

ncbi.nlm.nih.gov

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E (2013). "Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups". Thrombosis. 2013: 640723. doi:10.1155/2013/640723. PMC 3885278. PMID 24455237.
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. (December 2018). "Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review". Annals of Internal Medicine. 169 (11): 774–787. doi:10.7326/M18-1523. PMC 6825839. PMID 30383133.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. (February 2013). "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects". British Journal of Clinical Pharmacology. 75 (2): 476–487. doi:10.1111/j.1365-2125.2012.04369.x. PMC 3558798. PMID 22759198.
Cada DJ, Levien TL, Baker DE (June 2013). "Apixaban". Hospital Pharmacy. 48 (6): 494–509. doi:10.1310/hpj4806-494. PMC 3839491. PMID 24421512.

dailymed.nlm.nih.gov

"Eliquis- apixaban tablet, film coated Eliquis 30-day starter pack- apixaban kit". DailyMed. 26 November 2019. Retrieved 22 April 2020.
"Andexxa- andexanet alfa injection, powder, lyophilized, for solution". DailyMed. 8 January 2019. Retrieved 23 December 2019.

pubchem.ncbi.nlm.nih.gov

"Apixaban". PubChem, US National Library of Medicine. 27 August 2022. Retrieved 2 September 2022.

pfizer.com

"Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds". Pfizer (Press release). Archived from the original on 10 September 2015. Retrieved 25 December 2021.
"U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy" (Press release). Pfizer. 21 August 2014. Retrieved 26 February 2016.

semanticscholar.org

api.semanticscholar.org

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978. S2CID 43262809.

web.archive.org

"FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. This article incorporates text from this source, which is in the public domain.
"Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds". Pfizer (Press release). Archived from the original on 10 September 2015. Retrieved 25 December 2021.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). 5 August 2020. Archived from the original on 30 June 2023. Retrieved 30 June 2023.